{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122M Automated Microbiology System - Ticarcillin/clavulanate (1/2 - 128/2 \u03bcg/mL)"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K062687",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020321",
        "K020322",
        "K020323",
        "N50510",
        "K033557"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "October 24, 2006",
    "Summary Letter Received Date": "September 8, 2006",
    "Submission Date": "September 7, 2006",
    "Regulation Number(s)": [
        "21CFR866.1645"
    ],
    "Regulation Name(s)": [
        "Antimicrobial susceptibility test short incubation"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Ticarcillin/clavulanate"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates of Gram-negative aerobic and facultative anaerobic bacteria",
        "Pure culture isolates of Gram-positive bacteria"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix\u2122M Automated Microbiology System"
    ],
    "Method(s)/Technology(ies)": [
        "Broth based microdilution",
        "Automated susceptibility testing",
        "Redox indicator"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Minimal inhibitory concentration (MIC) determination"
    ],
    "Submission Type(s)": [
        "System",
        "Panel",
        "Reagent",
        "Instrument",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix\u2122M Automated Microbiology System using broth microdilution panels for automated antimicrobial susceptibility testing of ticarcillin/clavulanate against Gram-negative and Gram-positive bacteria.",
    "Indications for Use Summary": "Intended for rapid identification and quantitative determination of antimicrobial susceptibility (MIC) of most aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria from pure culture using Phoenix panels with ticarcillin/clavulanate, including additional organisms and removal of limitations for Pseudomonas species and Stenotrophomonas maltophilia.",
    "fda_folder": "Microbiology"
}